Health Care • Biotechnology: Pharmaceutical Preparations
$3.31 ▲ +0.07
(+2.16%)
MKT CAP: $356.7M • VOL: 18.78M
52W L $0 52W H $4
ROARABLE / RQD
D- • 40/100
PIOTROSKI
3 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$3
MEDIAN
$4
MEAN
$4
HIGH
$5
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CYPH TAPE
CYPH // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $4.01 | $3.81 | 2025-02-14 | $3.01 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $4.17 | $3.91 | 2025-02-06 | $3.11 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $3.77 | $3.64 | 2025-01-29 | $3.18 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $3.38 | — | 2025-01-17 | $3.24 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $2.91 | $3.14 | 2025-01-09 | $2.95 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $3.94 | $3.44 | 2024-12-18 | $2.88 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $3.21 | $3.34 | 2024-12-04 | $3.08 | -4.3% | 48% | C |